Evaluating the Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients
Launched by RENMIN HOSPITAL OF WUHAN UNIVERSITY · Feb 27, 2023
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how an automatic surveillance system can help monitor patients who have had polyps removed from their colon, a procedure known as postpolypectomy. The researchers want to see if using this smart system improves the rate at which patients get the follow-up care they need compared to traditional methods. Participants will be divided into three groups: one will use the automatic system, another will receive manual reminders, and the third will have no specific reminders at all. The goal is to find out which method works best for ensuring patients stay on track with their follow-up appointments.
To be eligible for this study, you need to be at least 18 years old and have had a colonoscopy. However, some individuals won't qualify, such as those without clear test results, those who can't be contacted, or those with certain health conditions. If you join the study, you'll be monitored based on the group you are assigned to. It's important to know that the trial isn’t recruiting participants yet, so there will be more information available as the study progresses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female aged 18 years or older who undergo colonoscopy.
- Exclusion Criteria:
- • 1)No pathological result.
- • 2) No or invalid contact information.
- • 3) The surveillance interval cannot be determined according to the surveillance guidelines, including poor bowel preparation, colorectal cancer or suspicious malignance, surgery or colorectal ESD history, those who fail to complete colonoscopy due to unbearable, pathological indications of not polyps, hamartoma or lymphoma polyps, history of ulcerative colitis, and so on.
- • 4) Has participated in other clinical trials, signed the informed consent form and is in the surveillance period of other clinical trials.
- • 5) Have drug or alcohol abuse or psychological disorder in the past five years.
- • 6)Pregnancy.
- • 7)Not suitable for recruitment after investigator evaluation because of other high-risk conditions.
About Renmin Hospital Of Wuhan University
Renmin Hospital of Wuhan University is a leading healthcare institution in China, renowned for its commitment to advancing medical research and clinical innovation. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in various medical fields to facilitate cutting-edge studies aimed at improving patient outcomes and healthcare practices. With a strong emphasis on ethical standards and patient safety, Renmin Hospital collaborates with various stakeholders to drive forward-thinking research initiatives that contribute to the global medical community. Its state-of-the-art facilities and multidisciplinary teams enable efficient trial execution, ensuring robust data collection and analysis in pursuit of transformative healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Jiangmen, Guangdong, China
Patients applied
Trial Officials
Honggang Yu, phD
Principal Investigator
Renmin Hospital of Wuhan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials